Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission

NCT06669143 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

19

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B Cell Lymphoma

Interventions

DRUG: Zanubrutinib
DRUG: Lenalidomide

Sponsor

Ruijin Hospital